Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study
Abstract Introduction An increasing body of evidence suggests a close association between COVID‐19 infection and the safety of PD‐1/PD‐L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. Material and Methods We...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70202 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132561628495872 |
|---|---|
| author | Kaili Liao Jinting Cheng Yujie Hu Beining Zhang Peng Huang Jie Liu Wenyige Zhang Huan Hu Xinyi Bai Yihui Qian Daixin Guo Kun Ai Yuchen Zhu Long Huang |
| author_facet | Kaili Liao Jinting Cheng Yujie Hu Beining Zhang Peng Huang Jie Liu Wenyige Zhang Huan Hu Xinyi Bai Yihui Qian Daixin Guo Kun Ai Yuchen Zhu Long Huang |
| author_sort | Kaili Liao |
| collection | DOAJ |
| description | Abstract Introduction An increasing body of evidence suggests a close association between COVID‐19 infection and the safety of PD‐1/PD‐L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. Material and Methods We conducted a retrospective analysis of cancer patients who received PD‐1/PD‐L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune‐related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter‐subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher's exact, chi‐squared, and Mann–Whitney U‐tests. Result The results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD‐1/PD‐L1 inhibitors, and alterations in hepatic and renal function (p > 0.05). Conclusion Our findings suggest that infection with COVID‐19 does not significantly impact the safety of PD‐1/PD‐L1 inhibitors in cancer patients. Most cancer patients used PD‐1/PD‐L1 inhibitors during COVID‐19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects. |
| format | Article |
| id | doaj-art-16380ea526be4809ab7dfd0e72330845 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-16380ea526be4809ab7dfd0e723308452025-08-20T02:32:11ZengWileyCancer Medicine2045-76342024-10-011319n/an/a10.1002/cam4.70202Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort studyKaili Liao0Jinting Cheng1Yujie Hu2Beining Zhang3Peng Huang4Jie Liu5Wenyige Zhang6Huan Hu7Xinyi Bai8Yihui Qian9Daixin Guo10Kun Ai11Yuchen Zhu12Long Huang13Department of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang ChinaSchool of Public Health, Jiangxi Medical College Nanchang University Nanchang ChinaThe 1st Clinical Medical College, Jiangxi Medical College Nanchang University Nanchang ChinaQueen Mary College, Jiangxi Medical College, Nanchang University Nanchang ChinaDepartment of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang ChinaSchool of Public Health, Jiangxi Medical College Nanchang University Nanchang ChinaQueen Mary College, Jiangxi Medical College, Nanchang University Nanchang ChinaSchool of Public Health, Jiangxi Medical College Nanchang University Nanchang ChinaSchool of Public Health, Jiangxi Medical College Nanchang University Nanchang ChinaThe 2nd Clinical Medical College, Jiangxi Medical College Nanchang University Nanchang ChinaSchool of Public Health, Jiangxi Medical College Nanchang University Nanchang ChinaQueen Mary College, Jiangxi Medical College, Nanchang University Nanchang ChinaThe 1st Clinical Medical College, Jiangxi Medical College Nanchang University Nanchang ChinaDepartment of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang ChinaAbstract Introduction An increasing body of evidence suggests a close association between COVID‐19 infection and the safety of PD‐1/PD‐L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. Material and Methods We conducted a retrospective analysis of cancer patients who received PD‐1/PD‐L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune‐related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter‐subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher's exact, chi‐squared, and Mann–Whitney U‐tests. Result The results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD‐1/PD‐L1 inhibitors, and alterations in hepatic and renal function (p > 0.05). Conclusion Our findings suggest that infection with COVID‐19 does not significantly impact the safety of PD‐1/PD‐L1 inhibitors in cancer patients. Most cancer patients used PD‐1/PD‐L1 inhibitors during COVID‐19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.https://doi.org/10.1002/cam4.70202cancerCOVID‐19 infectionimmune‐related adverse eventsPD‐1/PD‐L1 inhibitorpropensity score matching |
| spellingShingle | Kaili Liao Jinting Cheng Yujie Hu Beining Zhang Peng Huang Jie Liu Wenyige Zhang Huan Hu Xinyi Bai Yihui Qian Daixin Guo Kun Ai Yuchen Zhu Long Huang Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study Cancer Medicine cancer COVID‐19 infection immune‐related adverse events PD‐1/PD‐L1 inhibitor propensity score matching |
| title | Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study |
| title_full | Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study |
| title_fullStr | Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study |
| title_full_unstemmed | Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study |
| title_short | Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study |
| title_sort | evaluation of the safety of pd 1 pd l1 inhibitors for immunotherapy in patients with malignant tumors after covid 19 infection a single center cohort study |
| topic | cancer COVID‐19 infection immune‐related adverse events PD‐1/PD‐L1 inhibitor propensity score matching |
| url | https://doi.org/10.1002/cam4.70202 |
| work_keys_str_mv | AT kaililiao evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT jintingcheng evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT yujiehu evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT beiningzhang evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT penghuang evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT jieliu evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT wenyigezhang evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT huanhu evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT xinyibai evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT yihuiqian evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT daixinguo evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT kunai evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT yuchenzhu evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy AT longhuang evaluationofthesafetyofpd1pdl1inhibitorsforimmunotherapyinpatientswithmalignanttumorsaftercovid19infectionasinglecentercohortstudy |